8-K
filed June 12, 2026, 4:59 PM ET
ticker TBPH
CIK 0001583107
other material
confidence high
sentiment neutral
materiality 0.15
Theravance Biopharma shareholders elect all director nominees, ratify auditor, approve say-on-pay
Theravance Biopharma, Inc.
- All six director nominees elected with >98% of votes cast in favor, including Laurie Smaldone Alsup and Susannah Gray.
- Ernst & Young LLP ratified as independent auditor for FY 2026 with 46.5M for, 572.9K against.
- Non-binding advisory resolution on named executive officer compensation approved with 42.6M for, 221.2K against.
- Proxies represented 91.4% of outstanding shares (47.06M), quorum established.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Theravance Biopharma, Inc. shareholders approved Election of Directors at the 2026-06-12 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company’s Annual General Meeting held in 2027 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non-Votes Laurie Smaldone Alsup 42,725,649 124,187 53,867 4,156,175 Susannah Gray 42,231,530 618,306 53,867 4,156,175 Dean J. Mitchell 42,557,257 297,316 49,130 4,156,175 Donal O’Connor 42,535,463 319,110 49,130 4,156,175 Deepika R. Pakianathan 41,936,019 918,543 49,141 4,156,175 Rick E Winningham 42,474,538 377,274 51,891 4,156,175
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-12 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified: For Against Abstain Broker Non-Votes 46,471,340 572,896 15,642 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding the compensation of the Company’s named executive officers at the 2026-06-12 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non-Votes 42,631,324 221,196 51,183 4,156,175
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.